Enhancement of immunogenicity of murine lymphocytic leukemia cells by transfection with BCG heat shock protein 70 gene

2013 ◽  
Vol 15 (1) ◽  
pp. 1-5 ◽  
Author(s):  
Xiao-Ling Li ◽  
Chun-Ling Zhao ◽  
Qian Dong ◽  
Li-Rong Sun
1998 ◽  
Vol 10 (2) ◽  
pp. 101-109
Author(s):  
Tsunayuki KAKIMOTO ◽  
Atsuko NAGASAWA ◽  
Taijiro ISHIYAMA ◽  
Kunihiko FUKUCHI ◽  
Nobuyoshi TSURUOKA

2008 ◽  
Vol 99 (6) ◽  
pp. 1109-1116 ◽  
Author(s):  
Prabir K. Chakraborty ◽  
Soumyajit Banerjee Mustafi ◽  
Sudipto Ganguly ◽  
Mitali Chatterjee ◽  
Sanghamitra Raha

Blood ◽  
2005 ◽  
Vol 106 (7) ◽  
pp. 2506-2512 ◽  
Author(s):  
Januario E. Castro ◽  
Carlos E. Prada ◽  
Olivier Loria ◽  
Adeela Kamal ◽  
Liguang Chen ◽  
...  

AbstractThe zeta-associated protein of 70 kDa (ZAP-70) is expressed in patients with aggressive chronic lymphocytic leukemia (CLL). We found that ZAP-70+ CLL cells expressed activated heat-shock protein 90 (Hsp90) with high binding affinity for Hsp90 inhibitors, such as 17-allyl-amino-demethoxy-geldanamycin (17-AAG), whereas normal lymphocytes or ZAP-70- CLL cells expressed nonactivated Hsp90. Activated Hsp90 bound and stabilized ZAP-70, which behaved like an Hsp90 client protein only in CLL cells. Treatment with Hsp90 inhibitors such as 17-AAG and 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) induced ZAP-70 degradation and apoptosis in CLL cells but not in T cells, and also impaired B-cell receptor signaling in leukemia cells. Transduction of ZAP-70- CLL cells with an adenovirus encoding ZAP-70 activated Hsp90 and specifically rendered the leukemia cells sensitive to 17-AAG. These data indicate that Hsp90 is necessary for ZAP-70 expression and activity; that ZAP-70 is unique among Hsp90 clients, in that its chaperone-dependency is conditional on the cell type in which it is expressed; and also that ZAP-70 is required for cell survival and signaling in CLL. Additionally, ZAP-70 expression in CLL cells confers markedly heightened sensitivity to 17-AAG or 17-DMAG, suggesting that these or other Hsp90 inhibitors could be valuable therapeutically in patients with aggressive CLL. (Blood. 2005;106:2506-2512)


2001 ◽  
Vol 120 (5) ◽  
pp. A152-A152
Author(s):  
H SUZUKI ◽  
S NAGAHASHI ◽  
M MIYAZAWA ◽  
M MORI ◽  
H NAGATA ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document